12/16
04:05 pm
bbot
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/11
04:05 pm
bbot
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/10
04:05 pm
bbot
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
Low
Report
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
11/18
04:05 pm
bbot
BBOT to Participate in Upcoming December Investor Healthcare Conferences
Medium
Report
BBOT to Participate in Upcoming December Investor Healthcare Conferences
11/12
04:05 pm
bbot
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Low
Report
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
11/3
04:05 pm
bbot
BBOT to Participate in the Jefferies Global Healthcare Conference in London
Low
Report
BBOT to Participate in the Jefferies Global Healthcare Conference in London
10/30
05:45 pm
bbot
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
Low
Report
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
10/25
12:30 pm
bbot
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hypergly
Medium
Report
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hypergly
10/23
04:05 pm
bbot
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/13
04:05 pm
bbot
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Medium
Report
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics